Related Experiment Video
Updated: Mar 7, 2026
Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
Published on: February 10, 2023
Genotyping CYP2D6 by three different methods: advantages and disadvantages
Background:
CYP2D6 belongs to P450 superfamily, and is responsible for the metabolism of 25% of the drugs used clinically. Genetic variability of CYP2D6 affects individual drug or toxic response leading to differences in the drug outcome or toxicity mediating adverse drug effects. The different variant alleles are associated with increased, decreased, or abolished enzyme hydroxylation functions. The CYP2D6*10 (rs1065852, c.100C>T) allele is associated with reduced function and is one of the most studied alleles.
Methods:
The aim of this study was to perform three different methods (PCR-RFLP, TaqMan® Drug Metabolism Genotyping Assays, and Sanger Sequencing) for genotyping alteration c.100C>T, rs1065852 in a group of 24 Portuguese subjects (15 females and 9 males, mean age 70±9 years) and compare the results.
Results:
We found 16 samples homozygous for *1 allele and 8 heterozygous for *10 allele.
Conclusions:
The three methods provide concordant results suggesting that any of these techniques is a reliable and sensitive method for genotyping CYP2D6. However, we would recommend the use of TaqMan® Drug Metabolism Assays, given the advantages concerning time spending, straightforwardness, reliability, and accuracy.
Insights
Genetic variability in CYP2D6 enzyme function impacts drug response. This study compared three genotyping methods for the CYP2D6*10 allele, finding all reliable but recommending TaqMan assays for efficiency.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Genetic Variation
Background:
- Cytochrome P450 2D6 (CYP2D6) is crucial for metabolizing 25% of clinical drugs.
- Genetic variations in CYP2D6 influence drug efficacy and toxicity.
- The CYP2D6*10 allele (rs1065852, c.100C>T) is linked to reduced enzyme function.
Purpose of the Study:
- To compare three genotyping methods for the CYP2D6 c.100C>T (rs1065852) variant.
- To assess the reliability and sensitivity of PCR-RFLP, TaqMan® Assays, and Sanger Sequencing.
- To evaluate these methods in a Portuguese cohort.
Main Methods:
- Genotyping of the CYP2D6 c.100C>T variant using PCR-RFLP, TaqMan® Drug Metabolism Genotyping Assays, and Sanger Sequencing.
- Analysis of genetic alterations in 24 Portuguese subjects.
- Comparative assessment of the three genotyping techniques.
Main Results:
- All three methods yielded concordant results for CYP2D6 genotyping.
- 16 samples were homozygous for the *1 allele, and 8 were heterozygous for the *10 allele.
- The study identified the presence of the CYP2D6*10 allele in the studied population.
Conclusions:
- PCR-RFLP, TaqMan® Assays, and Sanger Sequencing are reliable for CYP2D6 genotyping.
- TaqMan® Drug Metabolism Assays are recommended due to their speed, simplicity, and accuracy.
- Accurate CYP2D6 genotyping is essential for personalized medicine.
